Hydroxychloroquine
Antimalarial; modulates immune response, inhibits TLR signalling
- Response rate
- ~57% response rate (UV data)
- Onset
- Weeks–months
- Route
- Oral 200-400 mg daily
- Line
- 1st
- IgM effect
- Partial complement improvement
Evidence summary
One of the first drugs shown effective in HUVS (Lopez et al. 1984). First-line for mild-to-moderate cutaneous disease with arthralgias. Part of the colchicine-HCQ-dapsone backbone used in the French nationwide study. Reported helpful in approximately 57% of UV patients.